Premium
Advances in chemotherapy for gynecologic cancer
Author(s) -
Smith Julian P.,
Rutledge Felix
Publication year - 1975
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197508)36:2+<669::aid-cncr2820360809>3.0.co;2-a
Subject(s) - medicine , chemotherapy , vincristine , ovary , abdomen , cancer , ovarian carcinoma , carcinoma , pelvis , ovarian cancer , gynecologic cancer , surgery , combination chemotherapy , oncology , cyclophosphamide
Considerable progress is being made in the chemotherapy of some gynecologic cancers. A random study comparing postoperative irradiation therapy with chemotherapy shows the two to be equally effective. Chemotherapy has the advantages of added safety and of being much less expensive for the patient. Postoperative chemotherapeutic treatment with VAC of patients with embryonal carcinoma of the ovary can prevent recurrence of this frequently fatal tumor. In some patients with advanced embryonal carcinoma of the ovary, chemotherapy with VAC may produce permanent remissions. Combined irradiation and chemotherapy with vincristine and actinomycin‐D may be curative for some patients with advanced sarcomas in the pelvis or abdomen. This treatment combination is associated with severe complications; however, some are preventable.